Lemborexant - Generic Drug Details

What are the generic sources for lemborexant and what is the scope of patent protection?

Lemborexant is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lemborexant has fifty-five patent family members in thirty-three countries.

One supplier is listed for this compound.

Summary for lemborexant

International Patents:	55
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	38
Patent Applications:	227
What excipients (inactive ingredients) are in lemborexant?	lemborexant excipients list
DailyMed Link:	lemborexant at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lemborexant

Constraining patent/regulatory exclusivity:

10,188,652

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for lemborexant

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Virginia Commonwealth University	PHASE2
National Institute on Drug Abuse (NIDA)	PHASE2
Woolcock Institute of Medical Research	PHASE2

See all lemborexant clinical trials

Pharmacology for lemborexant

Drug Class	Orexin Receptor Antagonist
Mechanism of Action	Cytochrome P450 2B6 Inducers Orexin Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for lemborexant

N05CJ	Orexin receptor antagonists
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

N05CM	Other hypnotics and sedatives
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for lemborexant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes	10,702,529		Y
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-001	Apr 7, 2020		RX	Yes	No	8,268,848		Y	Y
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes	11,026,944		Y
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-001	Apr 7, 2020		RX	Yes	No	10,702,529		Y

International Patents for lemborexant

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2703297	КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ЛЕЧЕНИЯ БЕССОННИЦЫ (COMPOSITIONS AND METHODS FOR TREATING INSOMNIA)
Russian Federation	2703297
New Zealand	609313	Cyclopropane compounds
South Korea	20130097776	CYCLOPROPANE COMPOUNDS
Poland	2626350

Market Dynamics and Financial Trajectory for LEMBOREXANT

Last updated: February 14, 2026

Current Market Position and Indication

Lemborexant, marketed as Dayvigo by Eisai, is an orexin receptor antagonist approved by the FDA in December 2019 for treating insomnia. It targets adults experiencing difficulties with sleep onset and/or maintenance. Its approval marked it as a competitor to established sedatives like zolpidem, suvorexant, and lemborexant's primary rival, Merck’s suvorexant.

Regulatory and Patent Landscape

Lemborexant holds patents extending into the late 2020s, with patent expiry expected around 2032. These patents cover the compound itself and specific formulations, providing a period of market exclusivity. Patent protections have enabled Eisai to establish a strong market position, especially in the US and select international markets.

Market Penetration and Revenue

Sales of Dayvigo reached approximately $119 million in 2022, with growth driven by expanding prescriptions and increasing awareness among healthcare providers. Sales accounted for an estimated 2.2% of the global sleep aid market, which was valued at around $5.4 billion in 2022. Analysts forecast compound annual growth rate (CAGR) for the sleep aid market at roughly 7% through 2027.

Eisai's strategic partnerships and marketing efforts focus on particular segments: older adults and insomniacs with comorbidities. The drug's favorable side-effect profile compared to benzodiazepines supports its uptake in these populations.

Competitive Landscape

Lemborexant faces competition from:

• Zolpidem (Ambien): Established, with US sales exceeding $350 million in 2022.
• Suvorexant (Belsomra): Pfizer/Merck product, with approximately $278 million in US sales in 2022.
• Melatonin and over-the-counter remedies: Significant share in less severe cases.

Despite competitive pressure, lemborexant's unique mechanism and safety profile support its continued growth prospects.

R&D and Pipeline Developments

Eisai invests in expanding lemborexant's indications. Confirmatory Phase 3 trials assess efficacy for circadian rhythm disorders and co-administration with antidepressants for comorbid depression-associated insomnia. These trials could broaden the drug's commercialization and open additional revenue streams.

Pricing Strategy and Reimbursement

In the US, Dayvigo is priced at approximately $650 per month, aligned with other prescription sleep aids. Second-generation drugs like lemborexant benefit from preferred formulary placement owing to favorable safety profiles, improving reimbursement prospects.

Market Risks and Challenges

• Generic Entry: Patent cliffs could occur by 2032, risking price erosion.
• Regulatory Scrutiny: The FDA emphasizes safety profiles for sleep aids, which could affect labeling and marketing.
• Market Saturation: Increasing competition from both branded and generics may plateau sales growth.

Financial Projections

Based on current sales figures and growth estimates, Eisai projects lemborexant revenue to reach approximately $300-400 million globally by 2027. This projection assumes a CAGR of 12-15%, driven by expanding indications and increased prescriber acceptance.

Eisai's R&D expenditure dedicated to lemborexant-related studies is approximately 10% of its sleep disorder pipeline investment. Margins are expected to improve as production scales, with gross profit margins estimated at 60% post initial commercialization phase.

Conclusion

Lemborexant's market trajectory hinges on maintaining its patent protections, expanding indications, and capturing growth in older adult populations and comorbid conditions. Competition remains stiff, but its differentiated safety profile affords strategic advantages. Financial growth depends on continued prescriber acceptance and the timing of patent expirations.

---

Key Takeaways

• Lemborexant (Dayvigo) earned $119 million in 2022 sales, with forecasts predicting growth to $300-400 million by 2027.
• It faces competition from zolpidem and suvorexant but benefits from a favorable safety profile.
• Patent protections extend until 2032, delaying generic entry.
• Pipeline efforts focus on expanding indications, which may bolster future revenues.
• Market risks include patent cliffs, regulatory scrutiny, and increasing generic competition.

---

FAQs

1. What factors are projected to influence lemborexant’s sales growth?
Market expansion through new indications, increased awareness among prescribers, and demographic shifts toward older populations with sleep disorders primarily drive sales. Regulatory approvals for additional uses could further boost growth.

2. How does lemborexant compare to other sleep aids in market share?
Lemborexant holds a small market share at approximately 2.2% globally as of 2022, trailing behind zolpidem and suvorexant, which command larger shares. Its growth depends on differentiation and broader indications.

3. When might generic versions of lemborexant enter the market?
Patent protections last until approximately 2032. Once they expire, generics are expected to enter rapidly, potentially eroding branded sales significantly.

4. What are the primary risks affecting lemborexant’s financial outlook?
Patent expiration, regulatory changes, competitive pricing from generics, and market saturation pose the main risks. Safety-related regulatory actions could also impact sales.

5. What are the promising pipeline developments for lemborexant?
Clinical trials for circadian rhythm disorders and combination therapy with antidepressants could expand its approved uses, creating new revenue streams and market opportunities.

---

Citations

[1] FDA. (2019). FDA approves Dayvigo for the treatment of insomnia.
[2] Eisai. (2022). Year-end financial report and sales data for Dayvigo.
[3] IQVIA. (2022). Global sleep aid market report.
[4] MarketWatch. (2022). Sleep aids market forecast 2022-2027.
[5] ClinicalTrials.gov. (2023). Ongoing lemborexant trial data.